Long term CMR follow up of patients with right ventricular abnormality and clinically suspected arrhythmogenic right ventricular cardiomyopathy (ARVC)
The Task Force Criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC) was updated in 2010 to improve specificity. There was concern however that the revised cardiovascular magnetic resonance...
Authors: Song Z, Gao R, Yan B Abstract Cardiovascular disease is still the main cause of morbidity and mortality worldwide. Currently, the frontier of research into cardiovascular disease is the field of non-coding RNA. In this review, information was collected on the use of micro-RNAs as non-invasive biomarkers and their role in pathophysiological processes and therapeutic applications. In the case of microRNA-1 and microRNA-133, the roles and regulatory mechanisms of them are reviewed for arrhythmia, myocardial infarction, diabetic cardiomyopathy, myocardial hypertrophy, cardiomyocyte differentiation, and cell re...
This study assessed the utility of SPARC-like protein 1 (SPARCL1) as a biomarker of maladaptive right ventricular (RV) function in patients with pulmonary hypertension (PH).Methods: In this prospective study, we examined SPARCL1 levels in 105 patients with adaptive (n = 34) and maladaptive RV (n = 32) pressure overload caused by PH, dilated cardiomyopathy (DCM, n = 18) with LVEF
This article reviews the diagnosis and treatment of heart disease in Duchenne muscular dystrophy as well as emerging therapies.
ConclusionsLiver transplantation and combined liver –kidney transplantation appears to benefit some patients with PA or MMA, respectively, but this approach does not provide complete correction of the metabolic defect and some patients remain at risk from disease-related and transplantation-related complications, including death. Thus, all treatmen t avenues should be exhausted before consideration of organ transplantation and the benefits of this approach must be weighed against the risk of perioperative complications on an individual basis.
Risk matrices categorize risk level based on the probability of an event occurring versus the severity of that event. As a risk assessment tool, they help anticipate future events, understand the tolerability of consequences, and design effective prevention or mitigation strategies. In the case of cardiac conditions that predispose to sudden cardiac death at a young age, such as hypertrophic cardiomyopathy, the severity of the outcome is always catastrophic. Where variability exists is in the probability of that outcome.
Purpose of review To provide a framework for approaching ventricular arrhythmias in the setting of cardiomyopathy, outline the latest evidence-based recommendations for catheter ablation and device therapy, and discuss novel treatment strategies. Recent findings Risk stratification of ventricular arrhythmias in systolic heart failure has evolved, with an increasing role for cardiac magnetic resonance imaging to identify underlying substrate and scar burden. Medical therapy for heart failure has greatly improved, and the role of primary prevention defibrillators in nonischemic cardiomyopathy has become more ambiguous. ...
Conclusion Atrial arrhythmia is common among patients with ARVC with the pooled prevalence of approximately 18%, which is substantially higher than the reported prevalence of atrial arrhythmia in the general population.
No abstract available
No abstract available
In Reply We agree with Dr Schwartz and colleagues that it would be worthwhile examining the time from the last anthracycline dose on the extent of CRT benefit. However, for CRT to work, there needed to have been concomitant conduction tissue disease because all the patients in our study had an accompanying LBBB contributing to the mechanical dyssynchrony that was corrected with CRT. The temporal relationship of the LBBB to the development of cardiomyopathy could influence the degree of response. We do not have data to examine the relationship between the last dose of anthracycline, the development of LBBB, and the onset of cardiomyopathy.